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Preprosthetic surgeries are generally dealt with surgical procedures performed to facilitate fabrication of prosthesis or improve
the prognosis of prosthodontic care. In general the surgical procedures include various soft and hard tissue procedures which
are restricted intraorally. Maxillofacial prosthodontics is not restricted to restorations performed intra-orally. Various extraoral
surgical procedures have come into light in the recent past which helps to improve the prosthodontic outcome of craniofacial
region. The current paper tries to elaborate various minimally invasive cosmetic reconstructive procedures and materials available
in recent times.
1.Introduction
Historically, aesthetic facial surgery has been dominated
by skin tightening and tissue removal procedures. These
facelift procedures were described initially as the elevation,
tightening, and excision of skin. Over the following decades,
these procedures changed considerably which now include
tightening of skin and deep structures, excision of excess
tissue, composite or multiplane dissection, repositioning
of ptotic tissue, and restoration of volume [1]. Tension
restoration surgery continues to be useful but is most
eﬀective when combined with volume restoration. Today’s
patients do not want to miss work or play and desire “wash-
and-wear” surgical procedures. Botulinum toxin type A
(Botox),Restylane,nonablativelasers,andfacialimplantsare
examples of minimally invasive cosmetic facial surgery.
2.FacialImplants
Implant materials for chin augmentation include Silicone,
GORE-TEX, and porous polyethylene. Porous materials will
make removal or revision of the implants diﬃcult [2].
Postoperatively, if a nonporous material becomes a problem,
it is easily repositioned or removed. Bone resorption is a
result of pressure and muscle function. In patients with
severely deﬁcient chin and hypertrophic mentalis muscle,
there may be resorption of underlying bone. Most patients
with a mild-to-moderate deﬁcient chin are well treated with
an alloplastic implant [3].
2.1.GORE-TEX. GORE-TEXisa type ofPTFEthathasbeen
used in humans as an implantable material for more than 26
years. It was ﬁrst used in 1971 for human vascular grafts. In
1983, Neel used this polymer in rabbits and recommended
its use in facial plastic surgery. Because vascular ingrowth is
limited, this polymer has been shown to be only minimally
integrated with the surrounding tissues. The pore sizes range
from 0.5 sto 30 microns, which is not an ideal diameter
for macrophage migration and tissue ingrowth but can be a
favourable environment for bacterial invasion and infection
(Figure 1).
Autogenous material, such as patient’s own adipose
tissue, can be harvested via syringe liposuction and injected
into the desired area [4]. Other autologous materials include
dermis, dermal-fat grafts, fascia, and galea. Human-derived
donor materials for facial augmentation include AlloDerm,
Cymetra (which is AlloDerm in a particulate micronized
form), CosmoDerm and CosmoPlast, Fascian particulate
fascia, and Fasciablast (which is fascia in diﬀerent forms,
including strands). In addition, xenografts, such as bovine-
derived collagen ﬁllers like Zyderm and Zyplast, are avail-
able. Dermalogen, a homologous compound composed
of diﬀerent forms of human collagen, is no longer avail-
able. More popular dermal ﬁllers include diﬀerent forms of2 International Journal of Dentistry
Figure 1: GORE-TEX.
Figure 2: Porous high-density polyethylene (PHDPE).
hyaluronic acid such as Restylane, Perlane, Juvederm, and
Hylaform. Synthetic materials include silicone (such as Sil-
skin), polyalkylimide (such as Bio-Alcamid), hydroxyapatite
(such as Radiesse), polylactic acid (such as Sculptra), and
polymethylmethacrylate (such as ArteFill). All are useful for
structural augmentation of the face.
2.2. PHDPE. Porous high-density polyethylene (PHDPE) is
currentlymarketedintheUnitedStatesunderthetradename
M e d p o r( P o r e xS u r g i c a l ,I n c ,C o l l e g eP a r k ,G a ) .I ti sf o r m e d
by sintering small particles of high-density polyethylene to
create a strong ﬁrm material that can be molded using
hot water [5]. Pore sizes range from 100 to 250µm, with
50% being larger than 150µm. This is important because
previous animal studies have shown that pore sizes greater
than 100µm encourage tissue ingrowth [6, 7].
Medpor comes in prefashioned models or can be tai-
lored to speciﬁc patient’s needs based on stereolithographic
reconstruction from a 3-dimensional CT scan. Medpor is
radiolucent on CT scans and MRI images, causing no
interference with postoperative imaging, although a new
version with titanium mesh embedded in the Medpor with
minimal scatter that is MRI safe is radiopaque. The basic
structure of Medpor is a simple carbon chain that makes
it the reference standard for an inert substance in assays
of tissue reaction [8]. Early studies of Medpor implants
demonstrated ﬁbroblast ingrowth that prevents capsule
formation and promotes stabilization of the implant [9,
10]. De Potter and colleagues demonstrated ﬁbrovascular
ingrowth in vivo in patients who underwent orbital Medpor
implantation (Figure 2).
They showed, through serial MRI examinations, en-
hancement as early as 1.5 months postoperatively. Over long
periods, bone eventually incorporates at the implant-bone
interface, providing additional stability [11].
2.3.Polytetraﬂuoroethylene. PTFEisasyntheticpolymerthat
is carbon and ﬂuorine based (CF2-CF2) and nonbiodegrad-
able in the human body. It is biologically inert, adding to
its appeal for use as implant material. Teﬂon is a type of
PTFE in a paste form that has been used in the treatment
of vocal cord disorders; however, its use has largely been
abandoned because of injection diﬃculties and marked
inﬂammatory reactions. Proplast [12], originally developed
in 1970, was used to coat orthopedic joint implants. Later,
Proplast II was used in facial plastic surgery. When used in
temporomandibularjoint(TMJ)surgery,Proplast,underthe
strong shearing forces caused by mastication, breaks apart
and induces a signiﬁcant inﬂammatory reaction. The Food
and Drug Administration (FDA) ultimately recalled Proplast
and Proplast II.
2.4. Advanta Facial Implants (ePTFE). Expanded polyte-
traﬂuoroethylene (ePTFE) is a woven polymer consisting of
ﬁbrilsofPTFEthatareconnectedvianodesofPTFE,creating
astructuresimilartomesh.ePTFEisFDAapprovedforfacial
augmentation.Originally,GORE-TEXstrandsusedinthelip
and nasolabial fold were not without problems. At times, the
implants were palpable or extruded (Figure 3).
Facial implants have been used for many years and have
included a plethora of materials. Contemporary choices
for ﬁllers include fat, expanded polytetraﬂuoroethylene
((ePTFE) GORE-TEX; W.L. Gore Co., Flagstaﬀ,A r i z o n a ) ,
Silicone,Silastic,polyethylene,bovinecollagen,humancolla-
gen,hydroxyapatite,acrylicmicrospheres,lacticacid,dermis,
fascia, and others [13]. Advanta facial implants (Atrium
Medical, Hudson, New Hampshire) were diﬀerent from the
Gore-Tex implants used previously. They were more silky,
soft, and pliable. The manufacturer attributes this look and
feel to a sintering process in which the material is heated
to impart these properties. In addition, the diﬀerence in
this implant is the unique dual-core construction. Advanta
implants are available in round or oval conﬁgurations and
have an outer, medium-porosity smooth core of 50 microns
and an inner, high- porosity soft core of 100 microns
(Figure 4).
3.New LipandWrinkle Fillers
Over the millennia, various substances have been injected
into the face, including wax, silicone, and animal products
[14]. Contemporary cosmetic facial surgery includes many
options to augment lips, folds, and wrinkles. For decades,
bovine collagen has been the “gold standard” for facial ﬁller
augmentation in the United States [15]. An overview of
injectable ﬁller substances can be confusing. There exist
many options, many ﬁllers, many substances, many materi-
als, and many claims of superiority. As stated earlier, bovine
collagen (Zyplast, Zyderm; Inamed Corp., Santa Barbara,International Journal of Dentistry 3
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Figure 4: Advanta facial implants (ePTFE).
California) dominated the United States market for over 2
decades.
3.1. Zyplast. This FDA-approved product is collagen based
and is composed of highly puriﬁed bovine dermal tissue.
The constituent material is obtained from the hides of steer
within a closed herd. The dermal ﬁller ranges of products
in this brand are fast, convenient, easy, nonsurgical tools to
treat facial lines and wrinkles. Zyplast is mainly a cosmetic
skin care treatment, injected into the skin to decrease the
visibility of deep facial wrinkles, face folds and augment
lip shape or size. It is a denser version of the common
and popular injection Zyderm, both of which are made
from collagen, a substance existing naturally within the skin
tissue in the body. Conditions in which this product can be
used include pronounced facial lines, scars, wrinkles, and lip
border deﬁning.
The treatment procedure involves four weeks prior
testing which include administration of Zyplast test implant
into the forearm to determine the sensitivity to the ﬁller.
Normally, only 3-4% of tested patients will have positive
reaction. During treatment, the implant is injected into the
skin by use of a ﬁne gauge needle into the areas to be
treated. This is a simple treatment, capable of being com-
pleted quickly and quite conveniently. The initial treatment
generally lasts for 3–6 months, and repeated treatments can
be undertaken to preserve the looks. Side eﬀects include
burning sensation, redness, bruising, stinging, and tempo-
rary swelling. The product was cleared for marketing by the
Food and Drug Administration (FDA) in 1981 and 1985,
respectively. Treatment results can always last for three to
six months. Eventually, the injectable collagen breaks down,
making it necessary for repeat treatments to maintain the
desired results. In case treatments are discontinued, collagen
will be reabsorbed, enabling the face to turn back to its
original contours, naturally.
3.2. Zyderm. They were introduced in the early 1980s and
until today remain widely used in over 40 countries with
one million treatments having been undertaken. Due to the
requirement of tests before treatment, its use has consid-
erably reduced in the UK as a result of newly introduced4 International Journal of Dentistry
products that do not require such tests. It is generically
composed of Bovine dermal collagen plus 0.3% lignocaine
and is made from cow skins.
Recommended tests before treatment should be per-
formed four weeks prior to the treatment by administration
of Collagen Test Implant, intradermally into the volar
forearm. This is for the determination of possibility of the
patientdeveloping sensitivitytotheimplants.Itistemporary
in lasting since the collagen breaks down totally over time
to a point where no trace of the ﬁller can be found,
hence repeat treatment is necessary. Product ranges include
Zyderm 1 implant, Zyderm 2 implant, and Zyplast which is
cross-linked with the chemical glutaraldehyde speciﬁcally for
strengthening the collagen ﬁbers. Eﬀects will last for a period
depending on lifestyle and implant placement. Expected
eﬀects are transient erythema (redness), pain, swelling,
itching, implant area tenderness, and discoloration. In some
cases, injected collagen can show on the skin as a small area,
raised or white at the region of treatment. Credible tests
for safety determination were carried out between 1976 and
1981 and the product was approved by the Food and Drug
Administration (FDA).
3.3. Restylane. Restylane is FDA approved and is one of most
popular ﬁllers today. Restylane with natural hyaluronic acid
makes treated areas fuller providing a natural, smooth, and
attractive look. Restylane binds to water and replaces volume
lost with sun damage and aging. It is used not only to ﬁll in
wrinkles, scars, and folds but also can provide a minifacelift
by enhancing and ﬁlling in the cheeks hollows, under eye
hollows, cheek bones, chin, and midface areas. The lips and
earlobesarealsowonderfulareasforRestylaneenhancement.
3.4. Arteﬁll. Arteﬁll is a permanent ﬁller that is approved by
the FDA. A skin test is necessary, and the product can be
injected1monthlater.ArteﬁllcontainsPMMAmicrospheres
and puriﬁed bovine collagen gel with an anesthetic for com-
fort during injection. It is a dual-acting injectable wrinkle
ﬁller that provides immediate and long-lasting results. First
Arteﬁll visibly corrects the wrinkle, then the microspheres
provide the permanent support the skin needs for enduring
wrinkle correction. The collagen disappears and the beads
promote the production of patients’ own collagen around
them and the result is permanent. It is an excellent ﬁller
for lines on the side of the mouth in someone who wants
a permanent result.
4.Botox
Botulinum toxin is a protein produced by the bacterium
Clostridium botulinum and is extremely neurotoxic. When
introduced intravenously in monkeys, type A of the toxin
exhibits an LD50 of 40–56ng, type C1 around 32ng, type D
3200ng, and type E 88ng, rendering the above types some
of the most powerful neurotoxins known. Popularly known
by one of its trade names, Botox or Dysport, it is used for
various cosmetic and medical procedures.
Botox is a fully sequenced 1295 amino acid chain
metalloprotease. It consists of a 97kd heavy chain connected
Figure 5: Botulinum toxin.
by a disulﬁde bond to a 52kd light chain. The heavy chain
binds to the cell membrane of the distal axon, which allows
the light chain to penetrate the cell membrane into the
cytoplasm. After it is inside the cell, it cleaves synaptosomal-
associated protein 25, an essential protein in the mechanism
that allows the acetylcholine-containing vesicles to fuse with
the cell membrane, thus depositing the neurotransmitter
into the synapse. By blocking this pathway, Botox prevents
the presynaptic release of acetylcholine to the correspond-
ing motor endplates, thereby directly aﬀecting the nerve.
Depending on the dose injected, Botox can produce a full
range of eﬀects, from mild weakness to full paralysis of a
g i v e nm u s c l e .A tt i m e s ,B o t o xi se v e nu s e do ns e l e c t i v ep a r t s
of a single muscle. This exacting control is necessary to
achieve facial rejuvenation while minimizing complications
in the lower face. Clinically, the rejuvenating eﬀects of Botox
persist for approximately 3 months in the lower face after
initialinjection,butthedurationofactiontypicallyincreases
after multiple treatments [16].
The ﬁrst study to describe the therapeutic application of
the toxin (in rhesus monkeys) was published by Scott (an
ophthalmologist) and colleagues [17] in 1973. Scott’s ﬁrst
publication that described its use in humans for strabismus
appeared in 1980. The ﬁrst study detailing the use of Botox
for cosmetic reasons was published in 1992 [18]. Soon
thereafter, other uses in the upper face and neck were
described in the medical literature [19–21]( Figure 5).
The pathogenesis of the wrinkle is important in deter-
mining how eﬀe c t i v eB o t o xw i l lb ei ne ﬀacing it. The use
of ﬁllers in the lower face and the use of Botox for the
upper face are stressed. When the rhytid is primarily caused
by overhanging ptotic skin, surgery will probably be the
most eﬀective treatment. When the rhytid is primarily or at
least signiﬁcantly caused by muscular action deforming the
overlying skin, Botox can be an extremely eﬀective treatment
in the lower face.
5. Commercial Names
BOTOX (onabotulinumtoxinA), RESTASIS (cyclosporine
ophthalmicemulsion)0.05%,LUMIGAN(bimatoprostoph-
thalmic solution) 0.03%, BOTOX Cosmetic (onabotulinum-
toxinA), the JUV´ EDERM family of dermal ﬁllers, and the
LAP-BAND Adjustable Gastric Banding System.International Journal of Dentistry 5
6. Conclusion
The materials and techniques described above are only few
of the wide array of materials commercially available for
facial reconstruction. The paper limits itself not to cover
other procedures like fat augmentation, minimally invasive
percutaneous collagen induction, suture suspension, and
facial liposuction. The paper not only brings to light some
of these recent trends but also has a purpose of considering
these extraoral minimally invasive procedures as part of
preprosthetic surgical preparation of the patient to provide
with improved prosthodontic care.
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